Arginetix-Immune Control merger targets pulmonary, vascular disorders
This article was originally published in Scrip
Arginetix, the Baltimore-based biopharmaceutical company developing small-molecule inhibitors of the enzyme arginase (scripnews.com, 7 October 2009), has broadened its technology base and strengthened its human resources by merging with Immune Control, a spin-off from Drexel University College of Medicine in Philadelphia.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.